Co-Diagnostics, Inc. Unveils $3.8 Million Common Stock Offering Under Nasdaq Guidelines

Co-Diagnostics, Inc. Announces a $3.8 Million Common Stock Offering

Co-Diagnostics, Inc. (Nasdaq: CODX), a leading player in the molecular diagnostics field, has announced an impressive registered direct offering aimed at raising $3.8 million. This move marks a strategic step for the company as it seeks to bolster its operational capital and drive further innovations within its patented diagnostic platform.

Offering Details

On September 17, 2025, Co-Diagnostics reported that it had engaged with several institutional investors to sell 9,619,000 shares of common stock at an enticing price of $0.40 per share. This offering, conducted at-the-market under the regulations set forth by Nasdaq, is expected to close by September 18, 2025, pending the usual closing conditions being met. The gross proceeds from this transaction are projected to stand at around $3.8 million, which will be used primarily for working capital and general corporate initiatives.

The company’s announcement emphasizes its ongoing commitment to expanding its capabilities and ensuring a robust financial base for future advancements. Maxim Group LLC is taking the role of the sole placement agent for this offering, overseeing the process to ensure a smooth transaction.

Background on Co-Diagnostics

Co-Diagnostics, Inc., headquartered in Utah, has made significant strides in the molecular diagnostics industry. It is known for its innovative technologies designed to detect and analyze nucleic acid molecules, such as DNA and RNA. The company utilizes its proprietary technology to create specific tests for the Co-Dx PCR at-home and point-of-care platform, focusing not only on infectious diseases but also genetic markers relevant to various applications.

This offering reflects the company’s intent to leverage its unique technology platform to improve healthcare solutions, aligning with its mission to advance diagnostics globally. Following the Securities and Exchange Commission's approval of the shelf registration statement on Form S-3 filed on April 6, 2023, the upcoming share sale adheres to all regulatory requirements, ensuring transparency for potential investors.

Investor Communication

Investors interested in acquiring shares can find detailed information through the forthcoming prospectus supplement related to the offering, which will be available on the SEC’s website. Co-Diagnostics stressed that this press release does not constitute an offer to sell or solicit an offer to buy, emphasizing compliance with all legal regulations governing securities transactions.

The forward-looking statements included in the release outline the expected closing of the offering and intended use of the proceeds, while highlighting the inherent risks involved in such financial strategies. Co-Diagnostics has assured stakeholders that they will be promptly updated about any significant developments.

Conclusion

In summary, Co-Diagnostics, Inc.'s direct offering of common stock represents a pivotal moment for the molecular diagnostics company, aimed at fueling future growth and innovation. As the world increasingly relies on advanced diagnostics, Co-Dx’s efforts to secure additional funding will play a crucial role in advancing its state-of-the-art technologies and meeting the growing healthcare demands.